Skip to content

AAN Robotic Therapy in SCI

Effect of Assist-as-needed Robot Aided Rehabilitation Strategies in Subjects With Incomplete Spinal Cord Injury

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02803255
Enrollment
14
Registered
2016-06-16
Start date
2014-05-31
Completion date
2015-09-30
Last updated
2016-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spinal Cord Injuries

Keywords

Injuries, Spinal Cord

Brief summary

The purpose of this study is to demonstrate that a robot-aided rehabilitation protocol that follows the assist-as needed paradigm provide statistically significant improvements in arm and hand motor functions when compared to robot-aided protocols that passively move patients' arms along pre-defined trajectories, in patients with incomplete spinal cord injury (SCI).

Interventions

DEVICEMAHI Exo-II

Sponsors

William Marsh Rice University
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

Twenty adults with chronic incomplete SCI (according to American Spinal Injury Association (ASIA) Impairment Scale (AIS) C-D level) will be recruited from TIRR and from the Houston area. Inclusion Criteria: 1. Providing written informed consent prior to any study related procedures; 2. Age between 18-75 years; 3. Diagnosis of chronic complete or incomplete spinal cord injury as defined by the American Spinal Injury Association Impairment scale classification and at least for 6 months; 4. Not being involved in any specific exercise program (e.g., NMES, FES) within the previous 3 months; 5. No planned alteration in upper-extremity therapy or medication for muscle tone during the course of the study; 6. Eligibility for standard rehabilitation at the time of enrollment (i.e., absence medical comorbidities that would prevent standard rehabilitation); 7. No condition (e.g., severe arthritis, extreme shoulder pain) that would interfere with valid administration of the measures or with interpreting motor testing;

Exclusion criteria

Subjects will be excluded if they have: 1. Any joint contracture or severe spasticity in the affected upper extremity, as measured by a Modified Ashworth Score \> than 3 out of 4; 2. Subject who cannot provide self-transportation to the study location.

Design outcomes

Primary

MeasureTime frame
Change in ARAT scoreDifference between values measured i) <1 week before treatment start and ii) <1 week after the end of the 2-4 week long treatment program

Secondary

MeasureTime frameDescription
Change in Modified Ashworth ScaleDifference between values measured i) <1 week before treatment start and ii) <1 week after the end of the 2-4 week long treatment program
Change in Grip Pinch Strength AssessmentDifference between values measured i) <1 week before treatment start and ii) <1 week after the end of the 2-4 week long treatment program
Change in Graded Redefined Assessment of Strength, Sensibility and PrehensionDifference between values measured i) <1 week before treatment start and ii) <1 week after the end of the 2-4 week long treatment program
Change in Smoothness metricsDifference between values measured i) <1 week before treatment start and ii) <1 week after the end of the 2-4 week long treatment programMeasured via analysis of point-to-point reaching movements performed with the robot. Extracted measures include the movement-arrest-period-ratio, the spectral arc length, and the normalized average speed
Change in smoothness metricsDifference between values measured i) treatment start day and ii) session 10 of the therapy program - 2-4 weeks after treatment startMeasured via analysis of point-to-point reaching movements performed with the robot. Extracted measures include the movement-arrest-period-ratio, the spectral arc length, and the normalized average speed

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 26, 2026